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Gestational diabetes triggers 
postpartum cardiac hypertrophy 
via activation of calcineurin/NFAT 
signaling
Nirmal Verma, Sarah Srodulski, Sathya Velmurugan, Amanda Hoskins, Vivek K. Pandey, 
Florin Despa & Sanda Despa*
Population-based studies identified an association between a prior pregnancy complicated by 
gestational diabetes mellitus (GDM) and cardiac hypertrophy and dysfunction later in life. It is 
however unclear whether GDM initiates this phenotype and what are the underlying mechanisms. 
We addressed these questions by using female rats that express human amylin (HIP rats) as a GDM 
model and their wild-type (WT) littermates as the normal pregnancy model. Pregnant and two months 
postpartum HIP females had increased left-ventricular mass and wall thickness compared to non-
pregnant HIP females, which indicates the presence of concentric hypertrophy. These parameters 
were unchanged in WT females during both pregnancy and postpartum periods. Hypertrophic  Ca2+-
dependent calcineurin/NFAT signaling was stimulated two months after giving birth in HIP females 
but not in the WT. In contrast, the CaMKII/HDAC hypertrophy pathway was active immediately after 
giving birth and returned to the baseline by two months postpartum in both WT and HIP females. 
Myocytes from two months postpartum HIP females exhibited slower  Ca2+ transient relaxation and 
higher diastolic  Ca2+ levels, which may explain calcineurin activation. No such effects occurred in 
the WT. These results suggest that a GDM-complicated pregnancy accelerates the development of 
pathological cardiac remodeling likely through activation of calcineurin/NFAT signaling.
Gestational diabetes mellitus (GDM) complicates between 6 and 26% of pregnancies  worldwide1–3. Its incidence 
is growing rapidly, consistent with increasing rates of metabolic syndrome and obesity in the general  population1,4 
and more advanced maternal  age1. While the condition is by definition transient, multiple studies found that 
women with a GDM-complicated pregnancy are at higher risk of developing type-2  diabetes1,5–7 and cardiovas-
cular disease later in  life7–13. In a cohort of > 47,000 women (10.3% were diagnosed with GDM), women with 
prior GDM had higher rates of non-invasive cardiac diagnostic procedures, angina pectoris and cardiovascular 
hospitalizations over a 10 year follow up period compared to women with uncomplicated  pregnancies10. Another 
large (> 1,500,000 pregnancies)  study8 revealed an association between GDM and higher risk of angina, myo-
cardial infarction and hypertension within 7 years postpartum. The association was maintained after adjusting 
for age, diabetes, obesity and hypertensive disorders in pregnancy. In yet another cohort that included over 
1,000,000 women, GDM was associated with a higher cumulative incidence of hospitalization for cardiovascular 
disease 25 years after  delivery11. A meta-analysis of data from over 5 million women revealed that GDM remains 
strongly associated with risk of future cardiovascular events even in women that do not develop type-2  diabetes13.
Further insights into the link between GDM and the risk for cardiovascular disease were provided by stud-
ies that compared heart structure and function in women with GDM versus women with normal pregnancies. 
Prospective studies reported larger left ventricular relative wall  thickness14,15 and  mass15 in women with GDM 
compared to those in women with normal pregnancies at 34–39 weeks of gestation. Appiah et al.12 analyzed 
data of all women from the Coronary Artery Risk Development in Young Adults (CARDIA) study that had 
echocardiograms recorded at the beginning and at the end of a 20 years period and went through at least one 
pregnancy in between (609 women in total, 64 with GDM). After adjusting for potential confounders including 
body mass index, blood pressure, lipid levels and incident type-2 diabetes, women with prior GDM had increased 
left-ventricular mass index, impaired relaxation and systolic dysfunction at the end of the study. Notably, human 
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studies cannot distinguish between GDM playing a causal role in this cardiac remodeling or being just an early, 
separate marker of a higher cardio-metabolic risk in particular individuals.
On short term, cardiac hypertrophy is a physiological, adaptive response to stress. Long term however, 
hypertrophy becomes pathological and is associated with a cellular switch to fetal gene expression, diastolic and 
systolic dysfunction and the occurrence of arrhythmias. Ultimately, pathological hypertrophy can progress to 
heart failure. Physiological cardiac hypertrophy occurs in normal  pregnancy16–19 as a result of volume overload 
(caused by the large increase in blood volume) and endocrine changes, particularly the surge in progesterone and 
 estrogen18–20. The molecular mechanisms underlying heart growth in pregnancy include activation of PI3K/Akt 
and MAPK/ERK  pathways18,21. In humans, heart size returns to the pre-pregnancy level within a few months after 
giving  birth16,17. Meanwhile, pathological hypertrophy is a major manifestation of heart disease in individuals 
with type-2  diabetes22–27 and occurs even in the absence of vascular  complications26,27.
Studies in animal models revealed that  Ca2+-dependent hypertrophy signaling, usually associated with 
pathological hypertrophy, contributes to heart growth in both type-2  diabetes28 and normal  pregnancy18,29. 
Both CaMKII/HDAC and calcineurin/NFAT signaling pathways are activated in rats with late-onset type-2 
 diabetes28. Notably, the signaling was initiated in the prediabetic, insulin-resistant phase, before the onset of overt 
 hyperglycemia28. In mice, the level and activity of calcineurin were elevated early in pregnancy and decreased 
below the baseline level in late  pregnancy18,29. Moreover, inhibition of calcineurin by cyclosporine A blocked 
pregnancy-induced hypertrophy in  mice29, which indicates that the calcineurin/NFAT pathway is not a simple 
bystander but actively contributes to cardiac hypertrophy in normal pregnancy.
While the mechanisms underlying cardiac hypertrophy during and after a GDM-complicated pregnancy are 
unknown, it is conceivable that some mechanisms are shared with normal pregnancy and type-2 diabetes. Here 
we used female rats with β-cell specific expression of the human isoform of the pancreatic hormone amylin and 
their wild-type littermates to assess the role of  Ca2+-dependent hypertrophy signaling in the cardiac remodeling 
triggered by GDM. We found that two months after a GDM-complicated pregnancy, female rats showed cardiac 
hypertrophy and activation of calcineurin/NFAT signaling. In contrast, the CaMKII/HDAC hypertrophy pathway 
was active at term and returned to baseline after giving birth in rats with both normal and GDM-complicated 
pregnancies. These data suggest that calcineurin/NFAT pathway may play a role in the cardiac hypertrophy that 
occurs in females with a prior GDM pregnancy.
Results
Gestational diabetes in HIP rat females. HIP  rats28,30,31 are obese Sprague–Dawley rats with pancreatic 
β-cell specific expression of the human variant of amylin, a pancreatic hormone that is processed in the same 
secretory vesicles as insulin and co-secreted with  it32. At 5–6 months of age, amylin level is ~ fourfold higher in 
plasma from heterozygous HIP versus WT females (Supplementary Fig. 1A). Amylin acts as a satiation agent 
by activating receptors in the brain and slows down the gastric  fluxes33,34. In agreement with this function, 
HIP females had lower body weight compared to their WT littermates (Supplementary Fig.  1B). Moreover, 
amylin was previously shown to reduce insulin-stimulated glucose uptake in  muscle35,36. Indeed, HIP females 
(5–6 months of age) showed impaired glucose tolerance compared to age-matched WT females (Fig. 1A) while 
fasting blood glucose level was similar (see time 0 in Fig. 1A). To avoid confounding factors introduced by these 
differences between WT and HIP females at baseline, we designed the study to compare longitudinally females 
that went through pregnancy with age- and genotype-matched females that were never pregnant.
At this stage, HIP and WT females were randomly assigned to pregnancy and control study groups and further 
randomized for euthanasia and heart collection at 1 day or 2 months postpartum. Glucose tolerance decreased 
during pregnancy in both WT and HIP females, with HIP females remaining significantly glucose intolerant 
compared to the WT (Supplementary Fig. 2, top: time course of blood glucose level in glucose tolerance tests; 
Fig. 1B,C: area under the curve in these glucose tolerance tests). By the time of weaning, glucose tolerance 
returned to the pre-pregnancy level in HIP females (Supplementary Fig. 2, middle; Fig. 1B) and even improved 
compared to the control group in WT females (Supplementary Fig. 2, middle; Fig. 1C). In HIP females, glucose 
tolerance tended to worsen again by two months postpartum (Supplementary Fig. 2, bottom; Fig. 1B). The fasting 
blood glucose level in two months postpartum HIP females was similar to that measured at baseline (Fig. 1D), 
indicating that they were still in a pre-diabetic state. In fact, fasting blood glucose was similar in all HIP and 
WT groups throughout the study (see time 0 in Supplementary Fig. 2). Glucose tolerance did not change sig-
nificantly over this time in either WT or HIP females from the control, non-pregnant group (Fig. 1B,C). Thus, 
heterozygous HIP females display the typical glucose intolerance of GDM. WT females were used a model of 
normal, uncomplicated pregnancy.
Cardiac hypertrophy after a GDM-complicated pregnancy in rat females. Transthoracic echocar-
diography was used to monitor heart size and function in WT and HIP females from the control and pregnancy 
groups at baseline, late pregnancy and two months postpartum (Tables 1, 2, Fig. 2A–F, Supplemental Fig. 3). In 
HIP females, the left-ventricular mass (Fig. 2B), thickness of interventricular septum (Fig. 2D) and thickness of 
the left-ventricular posterior wall (Fig. 2F) were significantly increased in the pregnancy versus control group in 
late pregnancy and remained elevated two months after giving birth. In contrast, heart size was not significantly 
changed during pregnancy and postpartum periods in WT females from the pregnancy group compared to the 
WT control group (Fig. 2A,C,E).
In agreement with the echocardiography data, the heart weight-to-body weight ratio was elevated two months 
after giving birth in HIP females from the pregnancy group compared to HIP females from the control group, 
while no significant differences occurred in WT females (Fig. 2G,H). Moreover, the level of the hypertrophic 
marker ANP was increased in hearts from postpartum HIP females but not in postpartum WT females compared 
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Figure 1.  HIP females as a model of gestational diabetes. (A) HIP females (5–6 months of age) have reduced 
glucose tolerance compared to WT littermates, but fasting blood glucose is similar (n = 25 for WT, 30 for 
HIP). (B,C) Area under the curve in glucose tolerance tests performed in HIP (B) and WT (C) females in the 
pregnancy (N = 17 HIP and 14 WT in total) and control (N = 13 HIP and 11 WT in total) groups at baseline 
(BL), late (19–20 days) pregnancy, at the time of weaning the pups and 2 months postpartum. (D) Fasting blood 
glucose in HIP females from the pregnancy group at baseline and 2 months postpartum (N = 8). Statistical 
analysis was performed using Two-way ANOVA with Bonferroni’s multiple comparisons post-test for data in 
panels A-C and paired Student’s t-test for data in panel D.
Table 1.  Echocardiography parameters in WT females from control and pregnancy groups. Measurements 
were performed at baseline, during late pregnancy and two months after giving birth. HR heart rate, bpm beats 
per minute, FS fractional shortening, EF ejection fraction, IVS,d and IVS,s thickness of interventricular septum 
in diastole and systole, respectively, LVID,d and LVID,s left-ventricular internal diameter in diastole and 
systole, respectively, LVPW,d and LVPW,s thickness of left-ventricular posterior wall in diastole and systole, 
respectively. *P < 0.05 vs. control group.
WT females Baseline Late Pregnancy Postpartum (2 mo)
N Control 11 Pregnancy 14 Control 11 Pregnancy 14 Control 6 Pregnancy 7
HR (bpm) 325 ± 8 332 ± 7 331 ± 14 349 ± 10 356 ± 17 331 ± 18
FS (%) 45.3 ± 1.7 46.4 ± 1.8 46.9 ± 2.1 54.0 ± 2.7 50.9 ± 2.3 47.8 ± 3.5
EF (%) 74.8 ± 2.0 75.9 ± 1.9 76.3 ± 2.3 82.6 ± 2.2 80.7 ± 2.3 76.9 ± 3.1
IVS,d (mm) 1.56 ± 0.05 1.65 ± 0.06 1.66 ± 0.08 1.74 ± 0.09 1.78 ± 0.14 1.71 ± 0.14
IVS,s (mm) 2.83 ± 0.07 2.93 ± 0.10 2.91 ± 0.10 3.41 ± 0.12* 3.38 ± 0.25 3.29 ± 0.24
LVID,d (mm) 7.23 ± 0.13 7.24 ± 0.10 7.18 ± 0.14 7.29 ± 0.22 7.21 ± 0.39 7.79 ± 0.26
LVID,s (mm) 3.96 ± 0.17 3.89 ± 0.16 3.82 ± 0.19 3.40 ± 0.27 3.66 ± 0.16 4.12 ± 0.33
LVPW,d (mm) 1.71 ± 0.05 1.66 ± 0.03 1.75 ± 0.05 1.94 ± 0.12 1.92 ± 0.07 1.80 ± 0.13
LVPW,s (mm) 2.77 ± 0.09 2.75 ± 0.08 2.89 ± 0.11 3.43 ± 0.23* 3.25 ± 0.10 3.09 ± 0.21
LV Mass (mg) 815 ± 25 843 ± 29 864 ± 44 936 ± 40 918 ± 28 1015 ± 81
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to their respective non-pregnant controls (Fig. 2I). The BNP level did not change with pregnancy in either HIP 
or WT females (Fig. 2J).
Together, these data indicate the presence of cardiac hypertrophy in the postpartum period following a GDM-
complicated pregnancy (HIP rats) but not a normal pregnancy (WT rats).
Enhanced activity of calcineurin/NFAT hypertrophy signaling in postpartum HIP rat females 
following a GDM-complicated pregnancy. Since the calcineurin/NFAT hypertrophy pathway is acti-
vated in both type-2 diabetes and early stages of normal pregnancies, we investigated whether enhanced cal-
cineurin/NFAT signaling contributes to the cardiac hypertrophy following a GDM-complicated pregnancy. In 
this pathway,  Ca2+/calmodulin-dependent activation of the phosphatase calcineurin leads to de-phosphorylation 
of NFAT, causing its translocation into the nucleus where it activates gene  transcription37. Thus, the activity of 
calcineurin/ NFAT pathway was assessed from the nuclear versus cytosolic localization of NFATc4 as measured 
by immunofluorescence in isolated cardiac myocytes (Fig. 3A–C). There was a tendency towards lower nuclear-
to-cytosolic NFATc4 ratio immediately (within 1 day) postpartum in hearts from both WT and HIP females 
compared to the respective control groups (Fig. 3A–C), in agreement with data indicating downregulation of 
this signaling pathway in late  pregnancy18,29. Two months after giving birth, this pathway returned to its baseline 
activation level in WT females (Fig. 3B). However, the ratio of nuclear-to-cytosolic NFATc4 was significantly 
larger in myocytes from two months postpartum HIP females compared to control (Fig. 3A,C), indicating re-
activation of this hypertrophy pathway following a GDM-complicated pregnancy.
To further evaluate the activity of calcineurin/NFAT pathway, we used immunoblot to measure the expression 
of calcipressin-1 (also known as RCAN1 or MCIP1), an endogenous calcineurin inhibitor whose expression is 
under the control of calcineurin/NFAT38–40. Calcipressin-1 expression was comparable in hearts from control, 
1 day postpartum and two months postpartum WT females (Fig. 3D,E). In contrast, calcipressin expression was 
mildly but significantly elevated in hearts from two months postpartum HIP females (Fig. 3D,F).
Since calcineurin is activated by an increase in cytosolic  Ca2+ concentration, we measured  Ca2+ transients 
triggered by field stimulation at various frequencies between 0.2 and 2 Hz in myocytes from control, one day 
postpartum and two months postpartum WT and HIP females (Fig. 4A,B).  Ca2+ transient amplitude was not 
significantly affected by the pregnancy and postpartum stages in either HIP or WT females (Fig. 4C,D). However, 
 Ca2+ declined more slowly in myocytes from 2 months postpartum versus control, not-pregnant HIP females 
(Fig. 4E), which resulted in a more pronounced rise in diastolic  Ca2+ levels upon an increase in the stimulation 
frequency (Fig. 4G). In contrast, no such differences occurred in myocytes from postpartum and control WT 
females (Fig. 4F,H).
Activation of CaMKII/HDAC hypertrophy signaling in pregnant rat females. CaMKII/HDAC 
signaling is another  Ca2+-activated hypertrophy pathway in which, upon phosphorylation by CaMKII, HDAC 
moves out of the nucleus, which facilitates gene  expression41. Using immunofluorescent staining of isolated 
myocytes, we found that HDAC4 is exported from the nucleus in hearts from WT and HIP females immediately 
after giving birth (Fig. 5), which suggests that the CaMKII/HDAC pathway is activated in both normal preg-
nancy and GDM. However, this pathway returned to its baseline activation level by two months postpartum in 
both WT and HIP females (Fig. 5).
Discussion
Several population-based retrospective studies in large human cohorts established a strong association 
between GDM and the development of cardiovascular disease later in  life7–13, including cardiac remodeling and 
 dysfunction12,14,15. Using female rats that express the human variant of the pancreatic hormone amylin specifically 
in the β-cells (HIP rats) as a GDM model and their WT littermates as controls, we found here that pathological 
cardiac hypertrophy is also present two months post-delivery in female rats with GDM-complicated pregnancies 
Table 2.  Echocardiography parameters in HIP females from control and pregnancy groups. Measurements 
were performed at baseline, during late pregnancy and two months after giving birth. * P < 0.05, ** P < 0.01, 
and *** P < 0.001 vs. control group.
HIP females Baseline Lategrant Pregnancy Postpartum (2 mo)
N Control 13 Pregnancy 12 Control 13 Pregnancy 12 Control 8 Pregnancy 7
HR (bpm) 333 ± 7 333 ± 9 333 ± 13 357 ± 11 338 ± 13 365 ± 16
FS (%) 44.1 ± 1.1 43.3 ± 1.9 45.9 ± 2.8 48.0 ± 2.4 46.6 ± 1.9 46.6 ± 3.9
EF (%) 73.9 ± 1.2 72.6 ± 2.3 74.6 ± 3.5 77.0 ± 2.4 76.2 ± 2.1 75.5 ± 4.0
IVS,d (mm) 1.55 ± 0.04 1.50 ± 0.10 1.51 ± 0.06 1.84 ± 0.07** 1.43 ± 0.06 1.92 ± 0.12***
IVS,s (mm) 2.69 ± 0.05 2.64 ± 0.12 2.78 ± 0.10 3.08 ± 0.09 2.84 ± 0.11 3.41 ± 0.17**
LVID,d (mm) 6.81 ± 0.12 6.99 ± 0.20 7.25 ± 0.25 6.63 ± 0.23 7.45 ± 0.16 6.87 ± 0.45
LVID,s (mm) 3.81 ± 0.12 3.97 ± 0.18 3.96 ± 0.32 3.50 ± 0.22 3.97 ± 0.13 3.51 ± 0.50
LVPW,d (mm) 1.62 ± 0.06 1.64 ± 0.07 1.62 ± 0.05 1.91 ± 0.12* 1.54 ± 0.06 1.86 ± 0.18
LVPW,s (mm) 2.57 ± 0.08 2.54 ± 0.09 2.71 ± 0.07 3.11 ± 0.15 2.53 ± 0.07 2.97 ± 0.34
LV Mass (mg) 716 ± 25 728 ± 48 740 ± 28 866 ± 46 750 ± 42 941 ± 82*
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Figure 2.  Cardiac hypertrophy in two months postpartum HIP females. (A–F) Left ventricular mass (A,B), 
diastolic thickness of the interventricular septum (C,D) and diastolic thickness of the left-ventricular posterior 
wall (E,F) in WT (A,C,E) and HIP (B,D,F) females from control and pregnancy groups at baseline (BL), 
late pregnancy and 2 months postpartum. (G,H) Heart weight-to-body weight ratio of WT (G) and HIP (H) 
females at one day and 2 months postpartum. (I,J) Expression of ANP (I) and BNP (J) in hearts from control 
(Ctl), one day postpartum and 2 months postpartum WT and HIP females. Top panels show representative 
examples while bottom panels show relative band intensities; the experiment was repeated 4 times. For BNP, 
the intensity analysis included the bands with molecular weights between 15 and 20 kDa. In panels (A–H), 
statistical significance was determined using Two-way ANOVA with the Bonferroni post-test to compare the 
pregnancy versus control groups at each timepoint. In panels (I,J), data for animals in control (not pregnant) 
groups sacrificed at the time when pregnancy groups were at 1 day and 2 months postpartum were pooled. For 
these panels, statistical analysis was performed using One-way ANOVA (P value is indicated on the graph) with 
Dunnett’s post-test for multiple comparisons.
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but not in females with normal pregnancies (Fig. 2). Human studies cannot discriminate between GDM as a cause 
of the ulterior cardiovascular disease or a condition that develops in, and thus identifies, women that already are 
at higher risk. Since we compared postpartum HIP females with HIP females that did not go through pregnancy, 
our data suggest that GDM triggers, or at minimum accelerates, the postpartum development of pathological 
cardiac remodeling/ hypertrophy.
During a normal pregnancy, the heart generally undergoes physiological, mild eccentric hypertrophy, 
characterized by a proportional increase in chamber size and wall  thickness18,42–44, as expected for volume 
Figure 3.  Nuclear versus cytosolic localization of NFATc4 in myocytes from HIP and WT females. (A) 
Examples of immunofluorescence images in myocytes from HIP females in the control (Ctl), 1 day postpartum 
(1d post) and 2 months postpartum (2mo post) groups. Cells were labeled with an anti-NFATc4 antibody. (B,C) 
Mean ratio of nuclear-to-cytosolic NFATc4 signal in cells from WT (B) and HIP (C) females in the control 
(WT: 4 females, 10–15 cells/rat; HIP: 6 females, 9–14 cells/rat), 1 day postpartum (WT: 3 females, 11–16 cells/
rat; HIP: 5 females, 7–13 cells/rat) and 2 months postpartum (WT: 4 females, 10–11 cells/rat; HIP: 4 females, 
9–12 cells/rat) groups. The number of cells per each rat is shown in Supplementary Table 1. (D–F) Expression 
of calcipressin-1 in hearts from control (Ctl), one day postpartum and two months postpartum WT and HIP 
females. Representative examples (D) and relative band intensities (E,F). Data for the sample loaded into Lane 
7 of the WT gel were excluded from analysis. Data for animals in control groups sacrificed at the time when 
pregnancy groups were at 1 day and 2 months postpartum were pooled. Statistical analysis was performed with 
a mixed model using the Nested One-Way ANOVA analysis in Prism 8.1.2 (panels B and C; P values are shown 
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overload-induced heart growth. However, one study reported increased thickness of the septal and posterior 
walls with no change in diastolic diameter in pregnant  women16, while an investigation in pregnant mice found 
hypertrophy characterized by decreased left-ventricular wall thickness and larger chamber  size19. Somewhat 
surprisingly, pregnant WT females did not show overt cardiac remodeling or hypertrophy in our study. The 
reasons for this are unclear but might reflect reduced ability of the heart to undergo physiological hypertro-
phy due to a more advanced age (~ 5.5 months of age). This is in line with studies reporting lack of exercise-
induced hypertrophy in aged  animals45,46. In contrast, our data suggest that GDM is associated with concentric 
Figure 4.  Ca2+ transients in myocytes from control (Ctl), 1 day and 2 months postpartum females. (A,B) 
Representative examples of  Ca2+ transients stimulated at 0.2, 0.5, 1 and 2 Hz in myocytes from control, non-
pregnant HIP females (A) and two months postpartum HIP females (B). (C,D)  Ca2+ transient amplitude in 
myocytes from HIP (C) and WT (D) females. (E,F) Decay time of  Ca2+ transients triggered by pacing at 0.5 Hz 
in myocytes from HIP (E) and WT (F) females. (G,H) Diastolic  Ca2+ as a function of stimulation frequency in 
myocytes from HIP (G) and WT (H) females. Measurements were done in females from control (WT: 6 females, 
3-4cells/rat; HIP: 9 females, 3–7 cells/rat), 1 day postpartum (WT: 6 rats, 3–6 cells/rat; HIP: 8 rats, 2–6 cells/rat) 
and 2 months postpartum (WT: 3 rats, 6 cells/rat; HIP: 5 rats, 3–7 cells/rat) groups. The number of cells per each 
rat is shown in Supplementary Table 2. Data for animals in control groups sacrificed at the time when pregnancy 
groups were at 1 day and 2 months postpartum were pooled. Statistical analysis was performed with Two-way 
ANOVA for panels C, D, G and H, and with a mixed model using the Nested One-Way ANOVA analysis in 
Prism 8.1.2 for panels E and F. Dunnett’s post-test was used to account for multiple comparisons.
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remodeling/hypertrophy, both at term and postpartum, as HIP females showed increased diastolic thickness of 
both interventricular septum (Fig. 2D) and posterior wall (Fig. 2F) with no significant change in left-ventricular 
diameter (Table 2) compared to HIP females that did not experience pregnancy. This is consistent with human 
data showing larger left-ventricular wall index at term in females with GDM compared to females with normal 
 pregnancies14,15.
Cardiac hypertrophy observed two months postpartum in female rats with GDM was associated with acti-
vation of calcineurin/NFAT signaling, as evidenced by the nuclear translocation of NFATc4 (Fig. 3A,C) and 
increased expression of calcipressin-1, a protein whose expression is often used as an indicator of NFAT activa-
tion by calcineurin (Fig. 3F). Calcineurin is activated by an increase in cytosolic  Ca2+ through binding of  Ca2+/
calmodulin. We found that  Ca2+ transient decay is slower and consequently diastolic  Ca2+ is higher in myocytes 
from two months postpartum versus control, not-pregnant HIP females (Fig. 4E). Thus, following each heartbeat 
 Ca2+ stays in the cytosol longer, which may underlie calcineurin activation.
The calcineurin/NFAT pathway is usually involved in pathological hypertrophy, caused for example by pres-
sure overload. However, this pathway is also activated in the early stage of normal pregnancies and is required for 
the pregnancy-induced heart  growth18,29. Activation of calcineurin in early pregnancy was attributed to higher 
progesterone  levels29, but the underlying mechanisms are not fully elucidated. We previously reported that 
calcineurin/NFAT signaling is activated in pre-diabetic, insulin-resistant male HIP rats through a mechanism 
related to cardiac deposition of aggregated  amylin28, a hormone that is hypersecreted along with insulin by the 
pancreatic β-cells in pre-diabetes. HIP rats express the human isoform of amylin in the pancreas. In contrast to 
Figure 5.  Nuclear versus cytosolic localization of HDAC4 in myocytes from HIP and WT females. (A) 
Examples of immunofluorescence images in myocytes from HIP females in the control (Ctl), 1 day postpartum 
(1d post) and 2 months postpartum (2mo post) groups. Cells were labeled with an anti-HDAC antibody. (B,C) 
Mean ratio of nuclear to cytosolic signal in cells from WT (B) and HIP (C) females in the control (WT: 3 
females, 10–12 cells/rat; HIP: 5 females, 9–12 cells/rat), 1 day postpartum (WT: 3 females, 10–12 cells/rat; HIP: 4 
females, 9–12 cells/rat) and 2 months postpartum (WT: 3 females, 10–11 cells/rat; HIP: 4 females, 6–10 cells/rat) 
groups. The number of cells per each rat is shown in Supplementary Table 3. Data for animals in control groups 
sacrificed at the time when pregnancy groups were at 1 day and 2 months postpartum were pooled. Statistical 
analysis was performed with a mixed model using the Nested One-Way ANOVA analysis in Prism 8.1.2 and 
Dunnett’s post-test for multiple comparisons.
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rodent amylin, the human variant is  amyloidogenic32, which favors amylin aggregation and deposition in the 
pancreas and peripheral organs, including the  heart28,47,48. In pre-diabetic HIP rats, amylin deposition leads 
to an increase in the sarcolemmal permeability to  Ca2+ and thus raises cytosolic  Ca2+ level, which activates 
 calcineurin28. Females with GDM exhibit glucose intolerance, which is usually associated with an increase in 
insulin and amylin secretion. Thus, the cardiac stress caused by higher levels of circulating amyloid-forming 
amylin may also contribute to calcineurin/NFAT activation in females with GDM.
CaMKII/HDAC signaling is another  Ca2+-dependent pathway that leads to expression of pro-hypertrophic 
genes. In contrast to calcineurin signaling, this pathway was active immediately after giving birth and returned 
to baseline by two months postpartum in both HIP and WT females (Fig. 5). This result suggests that the CaM-
KII/HDAC pathway may contribute to cardiac hypertrophy during pregnancy but not to the GDM-induced 
programing of heart growth later in life.
One limitation of the current study is that similar experiments cannot be performed in humans, which leaves 
open the question whether the mechanism identified here does account for the postpartum cardiac hypertrophy 
in women with prior GDM. Partial mechanistic validation could come however from studies in additional animal 
models. Moreover, the mechanism needs to be further validated by experiments where the calcineurin/NFAT 
pathway is inhibited during pregnancy.
In summary, we found that GDM results in concentric cardiac hypertrophy, likely due to activation of cal-
cineurin/NFAT pathway, two months after giving birth in female rats. The comparison of postpartum HIP females 
with non-pregnant HIP females suggests a causative role for GDM in the postpartum development of pathologi-
cal remodeling of the heart. Understanding the mechanisms through which GDM predisposes the mother to 
heart dysfunction, coupled with early detection of GDM, will allow clinicians to design effective lifestyle and/or 
pharmacological interventions during the pregnancy and postpartum periods to reduce the risk.
Methods
The study is reported in accordance with ARRIVE guidelines.
Experimental animals. All animal experiments were performed in accordance with the NIH Guide for the 
Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at 
the University of Kentucky. N = 53 obese Sprague–Dawley female rats that are heterozygous for expression of the 
human isoform of the pancreatic hormone amylin specifically in the β-cells (HIP  rats28,30,31) and N = 40 wild-type 
(WT) littermates were used in this study. HIP (25.4 ± 0.3 weeks of age) and WT (24.6 ± 0.5 weeks of age) females 
were randomly assigned to pregnancy and control study groups. Females in the pregnancy groups were paired 
for breeding with Sprague–Dawley males. N = 6 females assigned to pregnancy groups did not become pregnant 
and were excluded from the study. Females in both pregnancy and control groups were further randomized for 
euthanasia and heart collection at one day or two months postpartum. Rats had ad libitum access to food and 
water. At the end of the study, rats were anesthetized with 3–5% isoflurane (100%  O2) and deep anesthesia was 
verified by lack of reflex upon toe pinch. Rats were then euthanized by exsanguination following excision of the 
heart.
Glucose tolerance test. Standard glucose tolerance tests (GTT) were performed at baseline and when 
the pregnancy groups were at 18–20 days of pregnancy, 21 days postpartum and 2 months postpartum. Rats 
were fasted for 8 h, injected with glucose (2 g/kg of body weight, IP) and blood glucose was monitored every 
15–30 min for two hours using a glucometer (OneTouch Ultra).
Echocardiography. Transthoracic echocardiography was performed under anesthesia (0.5–3% isoflurane) 
at baseline and when the pregnancy groups were at 18–20 days of pregnancy and two months postpartum using 
a Vevo 2100 high-frequency ultrasound (VisualSonics, Toronto, ON, Canada). Two-dimensional imaging was 
used to identify the short-axis position. Five consecutive M-mode images in the short-axis view were then used 
for analysis of chamber size and heart function.
Immunoblot. Hearts were homogenized in homogenization buffer containing 150 mM NaCl, 50 mM Tris–
HCl, 50 mM NaF, 2% Triton X-100, 0.1% SDS, supplemented with phosphatase and proteases inhibitor cocktail 
set III (Calbiochem). Homogenates were then loaded onto polyacrylamide gels for SDS-PAGE electrophore-
sis, transferred to PVDF membranes, blocked with 5% milk and probed with primary antibodies against atrial 
natriuretic factor (ANP; Millipore AB2232, 1:1000), brain natriuretic peptide (BNP; Abcam ab239510, 1:1000), 
and calcipressin-1 (ThermoFisher 14869-1-AP, 1:1000). Equal protein loading was verified by re-probing for 
GAPDH (Abcam ab8245). Bands were detected by chemiluminescent signals using the enhanced chemilumi-
nescence method (SuperSignal West Dura Extended Duration Substrate, ThermoScientific, USA) and visualized 
with a G:BOX gel imaging system (SynGene, Cambridge, United Kingdom). Band intensity was measured using 
ImageJ software (NIH, Bethesda, USA). For each gel, the signal intensity was averaged over the control samples. 
Then, the signal intensity in all lanes was normalized to this average. This procedure was repeated on all tech-
nical replicates and the normalized signal intensity was averaged for each sample, followed by averaging over 
experimental groups.
Ventricular myocyte isolation. Rats were anesthetized with 3–5% isoflurane (100%  O2) and hearts were 
excised by cutting the aorta, mounted on a gravity-driven Langendorff perfusion system and perfused with 
a nominally  Ca2+ free medium containing 11.2  g/L Minimum Essential Medium (MEM; Sigma M0518), 40 
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Units/L human insulin, 10 mL/L Penicillin–Streptomycin, 4.8 mM  NaHCO3, 2 mM sodium pyruvate, 10 mM 
Na-HEPES, 10 mM HEPES and 3.5 μL/mL heparin (pH = 7.4) for 5 min to clear the blood. The heart was then 
perfused with a similar medium except that heparin was excluded and 0.1 mg/mL Liberase TH (Roche-Sigma), 
30 μM  CaCl2 and 8 mM taurine were added. When the heart became flaccid (~ 20 min), the tissue was cut into 
small pieces, dispersed, and filtered and the myocyte suspension was rinsed several times. Myocytes were kept 
at low  Ca2+ (30 μM) until ready to use.
Immunofluorescence. Freshly isolated myocytes were plated onto laminin-coated 8-well glass coverslips 
and fixed with 4% paraformaldehyde. Cells were then permeabilized with 50 µg/mL saponin (15 min), blocked 
with 10% goat serum and 10% BSA for one hour and incubated overnight at 4 °C with primary antibodies against 
NFATc4 (Santa Cruz sc-13036; 1:100 dilution) or HDAC4 (Santa Cruz sc-11418; 1:100 dilution). Myocytes were 
then washed (6x) with PBS containing 1% BSA and incubated with Alexa Fluor 488 conjugated anti-rabbit sec-
ondary antibody (ThermoFisher A11034; 1:50 dilution) for 2 h at room temperature. Cells were washed again in 
PBS and imaged with a laser scanning confocal microscope. Signal intensities were analyzed in Image J.
Ca2+ transient measurements. Freshly isolated myocytes were loaded with Fluo-4 AM (10  μM for 
20 min) and paced at 0.2, 0.5, 1 and 2 Hz through platinum electrodes in a standard Tyrode’s solution containing 
(in mM): 140 NaCl, 4 KCl, 1  MgCl2, 10 glucose, 5 HEPES, and 1  CaCl2 (pH = 7.4). Cells were paced for > 2 min at 
each frequency to allow  Ca2+ transients and contractions to reach steady-state. The transients were the recorded 
for 10–15 s using a Nikon Eclipse Ti microscope equipped with a Lambda DG-4 illumination system (Sutter 
Instrument, Novato, CA) and an Andor iXon CCD camera (Andor Technology, Belfast, UK). All experiments 
were done at room temperature (23–25 °C) and results are expressed as F/F0, where  F0 is the fluorescence inten-
sity when the cell is at rest.
Statistical analysis. Data are presented as mean ± SEM. For data in Figs. 1, 2, and 3D, statistical analysis 
of differences between groups was performed in Prism 8.1.2 using the student’s t-test, One-way ANOVA with 
Dunnett’s multiple comparisons test or Two-way ANOVA with Bonferroni post-test, as appropriate. Single-cell 
experiments in Figs. 3, 4 and 5 were analyzed with a mixed model using the Nested One-Way ANOVA analysis 
with Dunnett’s multiple comparisons post-test in Prism 8.1.2 software. Differences were considered statistically 
significant when P < 0.05. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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